How many stocks does FARALLON CAPITAL MANAGEMENT LLC own?

As of Q1 2026, FARALLON CAPITAL MANAGEMENT LLC holds 172 positions in their 13F portfolio.

What is FARALLON CAPITAL MANAGEMENT LLC's largest holding?

STATE STR SPDR S&P 500 ETF T at 8.5% of portfolio, worth $1.5B.

What is FARALLON CAPITAL MANAGEMENT LLC's total portfolio value?

$17.5B as of Q1 2026, tracked across 172 holdings.

Is FARALLON CAPITAL MANAGEMENT LLC a hedge fund?

FARALLON CAPITAL MANAGEMENT LLC is an institutional investment manager required to file SEC 13F reports. This includes hedge funds, mutual funds, pension funds, and other institutions managing over $100M.

How often does FARALLON CAPITAL MANAGEMENT LLC report?

13F filings are due quarterly, approximately 45 days after each quarter end.

How has FARALLON CAPITAL MANAGEMENT LLC's portfolio changed in Q1 2026?

View FARALLON CAPITAL MANAGEMENT LLC's latest portfolio changes, new positions, and exits for Q1 2026 on HoldingsIntel.

What is FARALLON CAPITAL MANAGEMENT LLC's investment strategy?

FARALLON CAPITAL MANAGEMENT LLC is classified as a Balanced Allocator fund based on HoldingsIntel's Fund DNA analysis of 6 behavioral dimensions.

HoldingsIntel

FARALLON CAPITAL MANAGEMENT LL Holdings Q1 2026 - Portfolio & Conviction Scores | HoldingsIntel

FARALLON CAPITAL MANAGEMENT LLC

Institutional investor · Portfolio as of Q1 2026

SEC EDGAR SourceSEC Filings

$17.5B

AUM

172

Positions

Q1 2026

Filing

Rating · 3.0

Quarterly Portfolio Change

Activity profile

$ moved · Q1'26

New21%Increased17%Decreased16%Exited46%

Composition

Equity vs derivatives

Equity87%Puts12%Calls0%

Holding period

Avg 2.3 years

<1Q25%1-4Q16%1-2Y12%2Y+48%

Q1 2026 Summary

Active quarter - 48 new positions, 24 exits, 29 increased. Top move: MSFT (INCREASED, conviction 62). Portfolio: $17.5B across 172 positions.

Portfolio Allocation

Top holdings by portfolio weight

STATE STR SP8.53%

RVMD7.54%

AMZN5.01%

MSFT4.95%

AON4.62%

BBIO3.96%

INVESCO EXCH3.94%

PTGX3.81%

NTRA3.66%

EXEL3.21%

Other3.14%

Position Outcomes

Best and worst performing positions by estimated return

Top Winners

COGT22Q held

COGENT BIOSCIENCES INC

Avg $6.86 · $439,019 est. P&L

Est. P&L

+376.71%

PTGX30Q held

PROTAGONIST THERAPEUTICS INC

Avg $21.66 · $511.2M est. P&L

Est. P&L

+371.76%

RVMD21Q held

REVOLUTION MEDICINES INC

Avg $35.04 · $1.5B est. P&L

Est. P&L

+315.72%

Top Losers

Upgrade to Pro to see the worst-performing positions.

View plans

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Top Holdings172 positions

Export CSV(Pro)

Activity:

Stock	Shares	Value	Weight	Price Trend	Avg Buy	Est. P&L	Held	Conviction
??STATE STR SPDR S&P 500 ETF T PUT	2.3M	$1.5B	8.5%	—	—	—	—	New —
RVMD REVOLUTION MEDICINES INC	13.6M	$1.3B	7.5%	—	$35.04	+315.72%	21 qtrssince 2021-Q1	Decreased 0
AMZN AMAZON COM INC	4.2M	$878.6M	5.0%	—	$225.22	+17.28%	4 qtrssince 2025-Q2	Decreased 0
MSFT MICROSOFT CORP	2.3M	$868M	4.9%	—	$345.04	+23.83%	30 qtrssince 2018-Q4	Increased 62
AON AON PLC	2.5M	$811M	4.6%	—	$330.15	-3.92%	9 qtrssince 2024-Q1	Decreased 0
BBIO BRIDGEBIO PHARMA INC	9.4M	$695.5M	4.0%	—	$38.59	+71.37%	7 qtrssince 2024-Q3	Increased 60
??INVESCO EXCHANGE TRADED FD T PUT	3.6M	$690.9M	3.9%	—	—	—	—	New —
PTGX PROTAGONIST THERAPEUTICS INC	6.3M	$669.2M	3.8%	—	$21.66	+371.76%	30 qtrssince 2018-Q4	Increased 60
NTRA NATERA INC	3.2M	$641.4M	3.7%	—	$74.46	+151.65%	20 qtrssince 2021-Q2	Decreased 0
EXEL EXELIXIS INC	13.1M	$562.3M	3.2%	—	$22.96	+117.27%	30 qtrssince 2018-Q4	Decreased 0
Showing 10 of 172 results.162 more with Pro.PROUpgrade to see all →